KR102336370B1 - 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제 - Google Patents

당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제 Download PDF

Info

Publication number
KR102336370B1
KR102336370B1 KR1020167033863A KR20167033863A KR102336370B1 KR 102336370 B1 KR102336370 B1 KR 102336370B1 KR 1020167033863 A KR1020167033863 A KR 1020167033863A KR 20167033863 A KR20167033863 A KR 20167033863A KR 102336370 B1 KR102336370 B1 KR 102336370B1
Authority
KR
South Korea
Prior art keywords
mmol
reaction mixture
alkyl
delete delete
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167033863A
Other languages
English (en)
Korean (ko)
Other versions
KR20160147049A (ko
Inventor
엘리자베쓰 에이. 쥬리카
전추 훙
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20160147049A publication Critical patent/KR20160147049A/ko
Application granted granted Critical
Publication of KR102336370B1 publication Critical patent/KR102336370B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y10S514/866—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020167033863A 2014-05-07 2015-05-06 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제 Active KR102336370B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989651P 2014-05-07 2014-05-07
US61/989,651 2014-05-07
PCT/US2015/029409 WO2015171722A1 (en) 2014-05-07 2015-05-06 Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

Publications (2)

Publication Number Publication Date
KR20160147049A KR20160147049A (ko) 2016-12-21
KR102336370B1 true KR102336370B1 (ko) 2021-12-06

Family

ID=53181359

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167033863A Active KR102336370B1 (ko) 2014-05-07 2015-05-06 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제

Country Status (33)

Country Link
US (4) US9873679B2 (enExample)
EP (1) EP3140296B1 (enExample)
JP (1) JP6483156B2 (enExample)
KR (1) KR102336370B1 (enExample)
CN (1) CN106458976B (enExample)
AR (1) AR100328A1 (enExample)
AU (1) AU2015256120B2 (enExample)
BR (1) BR112016024936A2 (enExample)
CA (1) CA2948161C (enExample)
CL (1) CL2016002809A1 (enExample)
CY (1) CY1120340T1 (enExample)
DK (1) DK3140296T3 (enExample)
EA (1) EA033250B1 (enExample)
ES (1) ES2674531T3 (enExample)
HR (1) HRP20180641T1 (enExample)
HU (1) HUE039288T2 (enExample)
IL (1) IL248668B (enExample)
MA (1) MA39427B1 (enExample)
MX (1) MX378160B (enExample)
MY (1) MY181959A (enExample)
NZ (1) NZ727146A (enExample)
PE (1) PE20161363A1 (enExample)
PH (1) PH12016502034B1 (enExample)
PL (1) PL3140296T3 (enExample)
PT (1) PT3140296T (enExample)
RS (1) RS57170B1 (enExample)
SG (1) SG11201609170UA (enExample)
SI (1) SI3140296T1 (enExample)
SM (1) SMT201800342T1 (enExample)
TN (1) TN2016000444A1 (enExample)
TR (1) TR201809633T4 (enExample)
TW (1) TWI659951B (enExample)
WO (1) WO2015171722A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170002543A (ko) * 2014-05-07 2017-01-06 브리스톨-마이어스 스큅 컴퍼니 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제
TR201809633T4 (tr) * 2014-05-07 2018-07-23 Bristol Myers Squibb Co Diyabet gibi hastalıkların tedavisine yönelik pirolidin GPR40 modülatörleri.
EP3509588B1 (en) 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
WO2018049324A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
JPWO2018181847A1 (ja) * 2017-03-31 2020-03-05 武田薬品工業株式会社 芳香環化合物
CN110947003B (zh) * 2017-08-21 2021-04-02 武汉大学 Gpr31抑制剂在制备治疗肾脏缺血再灌注损伤及相关疾病药物中的应用
CN111712494A (zh) 2018-02-13 2020-09-25 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP2024522718A (ja) 2021-06-16 2024-06-21 セルジーン コーポレーション 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物
CN116283699B (zh) * 2023-03-02 2025-02-11 遵义医科大学 一种合成氟烷基取代的吡咯烷的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011044073A1 (en) 2009-10-06 2011-04-14 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
WO2014078609A1 (en) 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US7939569B1 (en) * 2009-12-01 2011-05-10 Hoffmann-La Roche Inc. Aniline analogs as glycogen synthase activators
GB2498976A (en) * 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
EP2880034B1 (en) 2012-08-01 2016-06-22 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor
ES2605856T3 (es) 2012-11-16 2017-03-16 Bristol-Myers Squibb Company Moduladores GPR40 de dihidropirazol
US9133163B2 (en) * 2012-11-16 2015-09-15 Bristol-Myers Squibb Company Dihydropyrazole GPR40 modulators
MX2015005720A (es) 2012-11-16 2015-09-08 Bristol Myers Squibb Co Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
CA2947065C (en) 2014-05-07 2022-04-19 Croma-Pharma Gesellschaft M.B.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
EP3140294A1 (en) 2014-05-07 2017-03-15 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
TR201809633T4 (tr) * 2014-05-07 2018-07-23 Bristol Myers Squibb Co Diyabet gibi hastalıkların tedavisine yönelik pirolidin GPR40 modülatörleri.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011044073A1 (en) 2009-10-06 2011-04-14 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
WO2014078609A1 (en) 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators

Also Published As

Publication number Publication date
HUE039288T2 (hu) 2018-12-28
IL248668A0 (en) 2017-01-31
SI3140296T1 (en) 2018-06-29
IL248668B (en) 2019-09-26
US20190112293A1 (en) 2019-04-18
DK3140296T3 (en) 2018-07-23
CN106458976A (zh) 2017-02-22
PT3140296T (pt) 2018-06-27
ES2674531T3 (es) 2018-07-02
AR100328A1 (es) 2016-09-28
AU2015256120B2 (en) 2019-03-28
EA033250B1 (ru) 2019-09-30
NZ727146A (en) 2020-01-31
US10717725B2 (en) 2020-07-21
JP6483156B2 (ja) 2019-03-13
RS57170B1 (sr) 2018-07-31
WO2015171722A1 (en) 2015-11-12
TN2016000444A1 (en) 2018-04-04
MX2016013801A (es) 2017-03-09
TR201809633T4 (tr) 2018-07-23
CL2016002809A1 (es) 2017-03-24
US20200299267A1 (en) 2020-09-24
MA39427A1 (fr) 2017-11-30
CA2948161C (en) 2020-10-27
AU2015256120A1 (en) 2016-12-22
PH12016502034B1 (en) 2022-03-23
CY1120340T1 (el) 2019-07-10
EP3140296B1 (en) 2018-04-11
EA201692037A1 (ru) 2017-06-30
EP3140296A1 (en) 2017-03-15
SMT201800342T1 (it) 2018-09-13
US9873679B2 (en) 2018-01-23
KR20160147049A (ko) 2016-12-21
US20150322044A1 (en) 2015-11-12
BR112016024936A2 (pt) 2017-08-15
MY181959A (en) 2021-01-15
PL3140296T3 (pl) 2018-08-31
SG11201609170UA (en) 2016-12-29
CN106458976B (zh) 2020-05-22
CA2948161A1 (en) 2015-11-12
MA39427B1 (fr) 2018-09-28
PH12016502034A1 (en) 2017-01-09
JP2017514856A (ja) 2017-06-08
MX378160B (es) 2025-03-10
TW201625585A (zh) 2016-07-16
PE20161363A1 (es) 2016-12-17
TWI659951B (zh) 2019-05-21
US20180099949A1 (en) 2018-04-12
HRP20180641T1 (hr) 2018-06-01

Similar Documents

Publication Publication Date Title
KR102336370B1 (ko) 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제
JP6322202B2 (ja) ピロリジンｇｐｒ４０修飾因子
US10301260B2 (en) Pyrrolidine GPR40 modulators
US10017497B2 (en) Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes
HK1229325A1 (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
HK1229325B (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191205

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210311

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210907

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211202

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211202

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20241120

Start annual number: 4

End annual number: 4